Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Effects of Exclusive Enteral Nutrition on the Microbiome in Pediatric Inflammatory Bowel Disease

Completed

Conditions: Inflammatory Bowel Diseases

Interventions: Dietary Supplement: Exclusive Enteral Nutrition (EEN)
Drug: Prednisone

First Posted Date: 2015-08-13

Last Posted Date: 2017-05-02

Lead Sponsor: McMaster Children's Hospital

Target Recruit Count: 31

Registration Number: NCT02521064

Locations: 🇨🇦
McMaster Children's Hospital, Hamilton, Ontario, Canada

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Phase 1

Active, not recruiting

Conditions: Recurrent Prostate Carcinoma
Metastatic Prostate Carcinoma
Castration-Resistant Prostate Carcinoma
Stage IV Prostate Cancer AJCC v7

Interventions: Drug: Cabazitaxel
Drug: Enzalutamide
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Prednisone

First Posted Date: 2015-08-13

Last Posted Date: 2024-02-14

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 37

Registration Number: NCT02522715

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸
Portland VA Medical Center, Portland, Oregon, United States

Repeat Emergency Department Visits Among Patients With Asthma and COPD

Not Applicable

Terminated

Conditions: Asthma
COPD

Interventions: Drug: beclamethasone dipropionate
Drug: albuterol
Drug: Prednisone

First Posted Date: 2015-07-16

Last Posted Date: 2019-06-04

Lead Sponsor: State University of New York at Buffalo

Target Recruit Count: 6

Registration Number: NCT02499887

Locations: 🇺🇸
Erie County Medical Center, Buffalo, New York, United States

Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis

Phase 2

Completed

Conditions: Lung Cancer
Lung Metastases

Interventions: Drug: Prednisone
Drug: Nintedanib
Other: Placebo

First Posted Date: 2015-07-14

Last Posted Date: 2024-04-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 33

Registration Number: NCT02496585

Locations: 🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 9 locations

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

Phase 2

Completed

Conditions: Kidney Transplant

Interventions: Biological: Infliximab
Drug: Methylprednisolone
Drug: Mycophenolate Mofetil
Drug: Tacrolimus
Biological: Thymoglobulin®
Drug: Acetaminophen
Biological: Placebo for Infliximab
Drug: Loratadine
Drug: Prednisone
Drug: Diphenhydramine

First Posted Date: 2015-07-13

Last Posted Date: 2022-08-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 290

Registration Number: NCT02495077

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
University of California, Los Angeles, Los Angeles, California, United States

and more 12 locations

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Docetaxel-PNP
Drug: Ribociclib
Drug: Prednisone
Drug: Filgrastim

First Posted Date: 2015-07-10

Last Posted Date: 2022-08-31

Lead Sponsor: Rahul Aggarwal

Target Recruit Count: 43

Registration Number: NCT02494921

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

and more 3 locations

MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma

Completed

Conditions: Lymphoma, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin's Lymphoma, Lymphoma, Non Hodgkin, Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Hydroxydaunorubicin
Drug: Oncovin
Drug: Prednisone
Drug: Rituximab

First Posted Date: 2015-07-01

Last Posted Date: 2016-02-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 154

Registration Number: NCT02486952

Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent

Phase 4

Completed

Conditions: Prostate Cancer Metastatic

Interventions: Drug: cabazitaxel XRP6258
Drug: enzalutamide
Drug: prednisone
Drug: abiraterone acetate

First Posted Date: 2015-06-30

Last Posted Date: 2022-05-27

Lead Sponsor: Sanofi

Target Recruit Count: 255

Registration Number: NCT02485691

Locations: 🇧🇪
Investigational Site Number 056007, Brussels, Belgium
🇧🇪
Investigational Site Number 056005, Leuven, Belgium
🇫🇷
Investigational Site Number 250010, Clermont Ferrand, France

and more 62 locations

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Phase 1

Conditions: Adult Burkitt Lymphoma
MYC Gene Mutation
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
Diffuse Large B-Cell Lymphoma
Plasmablastic Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Ixazomib Citrate
Other: Laboratory Biomarker Analysis
Drug: Methotrexate
Drug: Prednisone
Biological: Rituximab
Drug: Therapeutic Hydrocortisone
Drug: Vincristine Sulfate

First Posted Date: 2015-06-25

Last Posted Date: 2022-02-21

Lead Sponsor: Northwestern University

Target Recruit Count: 38

Registration Number: NCT02481310

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

and more 2 locations

Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Melphalan
Drug: Prednisone

First Posted Date: 2015-06-17

Last Posted Date: 2015-06-30

Lead Sponsor: Janssen Korea, Ltd., Korea

Target Recruit Count: 171

Registration Number: NCT02474563

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy